par Hedskog, Charlotte;Parhy, Bandita;Chang, Silvia;Zeuzem, Stefan;Moreno, Christophe ;Shafran, Stephen S.D.;Borgia, Sergio S.M.;Asselah, Tarik;Alric, Laurent;Abergel, Armando;Chen, Jyh Jou;Collier, Jane;Kapoor, Dharmesh;Hyland, Robert R.H.;Simmonds, Peter;Mo, Hongmei;Svarovskaia, Evguenia
Référence Open Forum Infectious Diseases, 6, 3, ofz076
Publication Publié, 2019-03
Référence Open Forum Infectious Diseases, 6, 3, ofz076
Publication Publié, 2019-03
Article révisé par les pairs
Résumé : | Background. Hepatitis C virus (HCV) is currently classified into 8 genotypes and 86 subtypes. The objective of this study was to characterize novel HCV subtypes and to investigate the impact of subtypes on treatment outcome. Methods. Full-genome sequencing was performed on HCV plasma samples with <85% sequence homology of NS3, NS5A, and/ or NS5B to HCV genotype (GT) 1-8 reference strains. Results. A total of 14 653 patients with GT1-6 HCV infection were enrolled in clinical studies of sofosbuvir-based regimens. For the majority of the patients, a specific subtype could be assigned based on a close genetic relationship to previously described subtypes. However, for 19 patients, novel subtypes were identified with <85% homology compared with previously described subtypes. These novel subtypes had the following genotypes: 9 in GT2, 5 in GT4, 2 in GT6, and 1 each in GT1, GT3, and GT5. Despite the presence of polymorphisms at resistance-associated substitution positions, 18 of the 19 patients treated with sofosbuvir-containing therapy achieved SVR12. Conclusions. Nineteen novel HCV subtypes were identified, suggesting an even greater genetic diversity of HCV subtypes than previously recognized. |